These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21252079)

  • 1. Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials.
    Li Y; Taylor JM; Elliott MR; Sargent DJ
    Biostatistics; 2011 Jul; 12(3):478-92. PubMed ID: 21252079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bayesian approach to surrogacy assessment using principal stratification in clinical trials.
    Li Y; Taylor JM; Elliott MR
    Biometrics; 2010 Jun; 66(2):523-31. PubMed ID: 19673864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surrogacy assessment using principal stratification and a Gaussian copula model.
    Conlon A; Taylor J; Elliott MR
    Stat Methods Med Res; 2017 Feb; 26(1):88-107. PubMed ID: 24947559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.
    Conlon AS; Taylor JM; Elliott MR
    Biostatistics; 2014 Apr; 15(2):266-83. PubMed ID: 24285772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
    Renfro LA; Shi Q; Sargent DJ; Carlin BP
    Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models.
    Taylor JM; Conlon AS; Elliott MR
    Clin Trials; 2015 Aug; 12(4):317-22. PubMed ID: 25490988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accommodating missingness when assessing surrogacy via principal stratification.
    Elliott MR; Li Y; Taylor JM
    Clin Trials; 2013; 10(3):363-77. PubMed ID: 23553326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solutions for surrogacy validation with longitudinal outcomes for a gene therapy.
    Roberts EK; Elliott MR; Taylor JMG
    Biometrics; 2023 Sep; 79(3):1840-1852. PubMed ID: 35833874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A reflection on the causal interpretation of individual-level surrogacy.
    Alonso A; Van Der Elst W; Molenberghs G; Florez AJ
    J Biopharm Stat; 2019; 29(3):529-540. PubMed ID: 30773114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bivariate network meta-analysis for surrogate endpoint evaluation.
    Bujkiewicz S; Jackson D; Thompson JR; Turner RM; Städler N; Abrams KR; White IR
    Stat Med; 2019 Aug; 38(18):3322-3341. PubMed ID: 31131475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surrogacy validation for time-to-event outcomes with illness-death frailty models.
    Roberts EK; Elliott MR; Taylor JMG
    Biom J; 2024 Jan; 66(1):e2200324. PubMed ID: 37776057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.
    Collier W; Haaland B; Inker LA; Heerspink HJL; Greene T
    BMC Med Res Methodol; 2024 Feb; 24(1):39. PubMed ID: 38365599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing and evaluating biomarker combinations as trial-level general surrogates.
    Gabriel EE; Sachs MC; Daniels MJ; Halloran ME
    Stat Med; 2019 Mar; 38(7):1135-1146. PubMed ID: 30306600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling.
    Ghosh D; Taylor JM; Sargent DJ
    Biometrics; 2012 Mar; 68(1):226-32. PubMed ID: 21668903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative methods to evaluate trial level surrogacy.
    Abrahantes JC; Shkedy Z; Molenberghs G
    Clin Trials; 2008; 5(3):194-208. PubMed ID: 18559408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data.
    Papanikos T; Thompson JR; Abrams KR; Städler N; Ciani O; Taylor R; Bujkiewicz S
    Stat Med; 2020 Apr; 39(8):1103-1124. PubMed ID: 31990083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
    Tanaka S; Matsuyama Y; Ohashi Y
    Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian meta-analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations.
    Wheaton L; Jackson D; Bujkiewicz S
    Res Synth Methods; 2024 Jul; 15(4):543-560. PubMed ID: 38316618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm.
    Roberts EK; Elliott MR; Taylor JMG
    Stat Med; 2021 Dec; 40(29):6605-6618. PubMed ID: 34528260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Links between causal effects and causal association for surrogacy evaluation in a gaussian setting.
    Conlon A; Taylor J; Li Y; Diaz-Ordaz K; Elliott M
    Stat Med; 2017 Nov; 36(27):4243-4265. PubMed ID: 28786131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.